Silverarc Capital Management, LLC Immuno Gen, Inc. Call Options Transaction History

Silverarc Capital Management, LLC

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2023 Nov 13, 2023	BUY	$14.09 - $19.87 $3.52 Million - $4.97 Million	250,000 New	250,000 $3.97 Million
Q1 2023 May 15, 2023	BUY	$3.67 - $4.92 $3.29 Million - $4.41 Million	896,200 Added 386.29%	1,128,200 $4.33 Million
Q4 2022 Feb 14, 2023	BUY	$4.55 - $6.31 $1.06 Million - $1.46 Million	232,000 New	232,000 $1.15 Million
Q1 2022 May 13, 2022	BUY	$4.26 - $7.48 $1.28 Million - $2.24 Million	300,000 New	300,000 $1.43 Million

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Silverarc Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Silverarc Capital Management, LLC with notifications on news.